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Introduction: Recent developments concerning pressurized metered dose inhalers (pMDIs)
with inhaled corticosteroids (ICS) are the introduction of ciclesonide and the replacement of
propellants. As the results of in vivo studies depend on pMDIperformance, it is necessary to
evaluate pMDIs in vitro for delivered dose and particle size distributions under different
conditions.
Methods: Fluticasone 125 mg, budesonide 200 mg, beclomethasone HFA100 mg, and ciclesonide
160 mg were compared for delivered dose and particle size using laser diffraction analysis with
inspiratory flow rates of 10, 20 and 30 l/s.
Results: The volume median diameter of budesonide was 3.5 mm, fluticasone 2.8 mm, beclo-
methasone and ciclesonide both 1.9 mm. The mouthpiece retention was up to 30% of the
nominal dose for beclomethasone and ciclesonide, 11e19% for the other pMDIs. Lifespan, flow
rate, and air humidity had no significant influence on particle size distribution. The delivered
dose of beclomethasone, budesonide, and ciclesonide remained constant over the lifespan.
The delivered dose of fluticasone 125 decreased from 106% to 63%; fluticasone 250 also
decreased whereas fluticasone 50 remained constant.
Conclusions: There is a significant difference in median particle size distribution between the
different ICS pMDIs. Air humidity and inspiratory flow rate have no significant influence ontered dose inhaler; ICS, inhaled corticosteroid; PSD, particle size distribution; CFC, chlorofluoro-
, laser diffraction analysis, FP, fluticasoneproprionate, BUD, budesonide; BDP, beclomethasone
F, fine particle fraction; MMAD, mass median aerodynamic diameter; VMD, volume median diameter.
2863385; fax: þ31 58 2863390.
nb.nl (T.W. de Vries).
9 Elsevier Ltd. All rights reserved.
1168 T.W. de Vries et al.particle size distribution. Ciclesonide 160 and beclomethasone 100 deliver the largest fine
particle fractions of 1.1e3.1 mm. The changes in delivered dose during the lifespan for the flu-
ticasone 125 and 250 may have implications for patient care.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
For the treatment of asthma the inhalation of medication is
preferred and its effectiveness is widely appreciated.1,2
The preferred size of the inhaled particles for deposition in
both central and peripheral airways is claimed to be
1e5 mm for adults,3 and 1.1e3 mm for children.4,5 The
delivered dose as percentage of the label claim as well as
the particle size distribution (PSD) within the delivered
dose has major influence on the site and amount of drug
deposited in the airways.
Recent developments include the switch from chloro-
fluorocarbon (CFC) to hydrofluoroalkane (HFA) containing
formulations for environmental reasons. This switch resul-
ted in dramatic changes in plume properties6 and particle
size distributions in the aerosol.7 For instance, for beclo-
methasone dipropionate (BDP) the same serum levels from
a CFC-MDI as from only half the dose with an HFA-MDI after
inhalation have been reported.8 As the results of in vivo
studies are largely dependent on pMDI performance,
a change in pMDI should be thoroughly investigated to
interpret in vivo studies with caution.
Furthermore ciclesonide (CIC), a new inhaled cortico-
steroid, was introduced. Ciclesonide is a prodrug which is
converted into the active metabolite in the airways. Its high
protein binding allows its use only once daily. It has been
formulated as an aerosol solution for a pMDI with a hydro-
fluoroalkane as propellant, and most of the particles
produced are claimed to be between 1 and 5 mm.9
To the best of our knowledge, no studies have been
published in which the consistency of delivered dose and
physical properties of the aerosol of ciclesonide are
compared with other aerosols. Information about delivered
dose and PSD is essential for both in vitro studies and
clinical trials.
This prompted us to compare the ciclesonide 160 mg/
dose pMDI with three other widely used pMDIs containing
ICS: fluticasone 125 mg/dose, budesonide 200 mg/dose, and
beclomethasone 100 mg/dose on their fine particle doses
(1e5 mm) and the influence of lifespan of the pMDI, flow
rate, and relative air humidity on the aerosol properties.
Materials and methods
Pressurized metered dose inhalators were obtained from
the local hospital pharmacy. The pMDIs tested were: fluti-
casone dipropionate 125 mg/dose (FP, Flixotide, Glax-
oSmithKline); budesonide 200 mg/dose (BUD, Pulmicort,
AstraZeneca); ciclesonide 160 mg/dose (CIC, Alvesco,
Nycomed); and beclomethasone dipropionate 100 mg/dose
(BDP, Qvar, Teva). The CIC and BDP pMDIs are CFC-free
and contain clear drug solutions; FP contains a CFC-free
suspension whereas BUD contains a suspension in a mixture
of CFC propellants. Table 1 compares some properties of
the pMDIs studied.Measurement of delivered dose
pMDIs were connected to a filter system with Gelman glass
filters A/E, P/N 61663; diameter 50 mm (Gelman Sciences,
Ann Arbor, Michigan, USA). The filter system was supplied
with a flow control unit and a solenoid valve with timer to
set the flow rate to 20 l/min and suction time to 3 s. The
suspension pMDIs were shaken for at least 10 s before doses
were fired with the mouthpiece in a coupling flange with
seal to prevent suction of false air and loss of aerosol. Time
between firing of subsequent doses was at least 60 s to
prevent excessive cooling of the pMDIs.
For three different devices (of the same batch) per type
of inhaler, 15 individual doses were collected in the filter
and analysed subsequently: five doses were taken from the
beginning, five from the middle and five towards the end of
the lifespan of the pMDI. The remaining doses in between
were collected in groups of 5e40 and analysed together.
The first ten doses of each new pMDI were wasted. Filter
and mouthpiece retentions were dissolved in ethanol
(analytical grade) and the drug solutions were analysed
with a spectrophotometer (Unicam UV 500, ThermoSpec-
tronic, UK) at 236 nm for fluticasone, 244 nm for budeso-
nide, 243 nm for ciclesonide, and 239 nm for
beclomethasone after it was checked with standard drug
solutions added to filter depositions, so that the propellants
in the drug formulations did not disturb the spectrophoto-
metrical analysis. Checks have also been done on filter
adsorption and the release of ethanol soluble components
from the plastic mouthpiece parts.
Particle sizing in the aerosols
For measurement of the particle size distributions (PSDs) in
the aerosols from the pMDIs we used a laser diffraction
apparatus (Sympatec Helos BF Magic) with inhaler adapter
(Inhaler 2000, Sympatec, Clausthal-Zellerfeld, Germany).
The inhaler adapter has a flow controller and solenoid valve
with timer to adjust to the desired inspiratory flow rate and
suction time. The flow rate was measured with a venturi-
meter. Unless indicated otherwise, suction of the aerosol
through the laser beam was at a constant flow rate of 10 l/
min during 3 s. This was decided after it was checked with
time sliced measurements that this time is sufficiently long
enough to draw the entire aerosol from the pMDI through
the laser beam. All measurements were started on an
optical signal on detector channel 30 (for fine particles) of
0.2%. The relative humidity in the laboratory (at a room
temperature of 20e22 C) was varied between low (approx.
30%), median (approx. 55%) and high (approx. 75%) to
investigate the effect of ambient conditions on the particle
size distribution.
A 100 mm (R3) lens was used with a measuring range of
0.5e175 mm and calculations were made with the
Fraunhofer theory after it was checked that no
Table 1 Some physical properties of the metered dose inhalers and actuators studied, measurements in millimetres.
Name Shape of mouthpiece Dimensions
mouthpiece (mm)
Distance of nozzle
to mouthpiece
end (mm)
Propellants/solvents Suspension
solution
Fluticasone Oval, flattened sides 15 10 21 Tetrafluorethane Suspension
Budesonide Oval 18 13 27 Trichlorofluormethane,
dichlorodifluoromethane
Suspension
Beclomethasone Circular 16 diameter 33 Norflurane/ethanol Solution
Ciclesonide Circular 16 diameter 33 Norflurane/ethanol Solution
Results of an in vitro study, using laser diffraction analysis 1169overestimation of fine particles occurred. Ghost peaks from
propellant(s) were removed with forced stability. No sheath
or counter flow through the adapter was added to the
aerosol cloud and the distance from the exit of the
mouthpiece to the laser beam was fixed to 50 mm after it
was checked that this yields realistic size distributions. The
pMDI was fired manually and the particle size distributions
in the aerosol were measured for five doses taken from the
beginning, five from the middle and five towards the end of
the lifespan of the pMDI. Additionally, the effect of flow
rate (10, 20, and 30 l/s) on the PSD was determined. Data
per flow rate are the mean of 3 series of 5e10 doses in
which each series is for a different pMDIs from the same lot.
PSDs are presented as X10-, X50- and X90-values derived from
the cumulative volume distribution curves as a function of
the particle diameter.
Statistics were performed using SSPS for Windows
(version 13.0) and all tests were performed two sided,
a p< 0.05 was considered statistically significant.
Results
Fig. 1 shows the mean metered dose (with maximum and
minimum values obtained) as percent of the label claim
from the three different devices of the same batch for all
four pMDIs. In Fig. 1 the mean, maximum and minimum per0
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Figure 1 Mean metered dose (for all doses) as percent of label cla
same lot with spread bars indicating the maximum and minimum val
200 mg/dose; BDPZ beclomethasone 100 mg/dose; CICZ ciclesoniddevice are for all doses, except for the first ten which were
intentionally wasted. As expected there is a spread in
metered dose for every individual pMDI. The variation is
particularly extreme for at least two of the FP pMDIs,
varying from 62% to 158%, respectively from 72% to 162% of
the label claim for the devices 1 and 2, this is statistically
significant. The mean metered dose is approximately 10%
higher for CIC than for the other pMDIs, but the mouthpiece
retention in this inhaler is higher too: 30% versus 11e19%
for the other pMDIs. As a result, the delivered dose from CIC
is more or less the same as that from the FP and BUD pMDI:
on average 85% of the label claim. Only the BDP pMDI has
a slightly lower delivered dose of 70% of the label claim.
Fig. 2aed shows the consistency of the delivered doses
for all devices within their lifespan. It can be seen that
there is a small, not clinically significant spread between
the delivered doses of BDP and CIC and that two BUD pMDIs
exhibited a low output at the start after having already
wasted the first 10 doses, one of them was statistically
significant. The delivered dose of FP pMDI decreased
statistically significantly with the number of doses taken to
less than 70% of the output in the first actuations. Because
we were surprised by this result we studied twelve addi-
tional FP 125 mg pMDIs taken from different lots, and also
measured (in duplo) the delivered dose of FP 50 mg and
250 mg for comparison. Fig. 3 summarises the mean valuesBD
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Figure 2 aed): Delivered dose in mg at the start (S1eS5), the middle (M1eM5) and the end (E1eE5) of the lifespan of the same
device. FPZ fluticasone 125 mg/dose; BUDZ budesonide 200 mg/dose; BDPZ beclomethasone 100 mg/dose; CICZ ciclesonide
160 mg/dose.
1170 T.W. de Vries et al.with spread bars showing maximum and minimum doses
obtained. It was found that the output of FP 50 remains
constant. However, the delivered dose of FP 250 also
decreased statistically significant with the number of doses
taken from the device.
Characteristic values (X10, X50 and X90) from the cumu-
lative volume distributions in the aerosol are presented in0
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Figure 3 Changes in the delivered dose from fluticasone (FP)
50, 125 and 250 mg with the cumulative number of doses taken
from the same device. Data points for FP 125 mg are the mean
of 15 devices (from five different batches); those for FP 50 and
250 mg are the mean of two devices (from different batches).
Spread bars indicate the maximum and minimum values
obtained.Fig. 4. The X50 of FP (3.5 mm) is significantly greater than all
others, and the X50 of BUD (2.8 mm) is significantly greater
than those of BDP and CIC (1.9 mm for both devices). Also
the spread in droplet size is much smaller for BDP and CIC.
FP 125 mg showed a great inter-device spread in size
distribution; mean values for the median droplet diameter
varied between 2.1 and 3.8 mm for individual devices from
different batches, this is statistically significant. For BDP0
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Figure 4 Particle size distribution of within lifespan of the
pMDI for fluticasone (FP) 125 mg, budesonide (BUD) 200 mg, HFA
beclomethasone (BDP) 100 mg, and ciclesonide (CIC) 160 mg at
a suction of 10 l/min through the laser beam. S, M and E refer
to doses taken at the start, middle and end of the lifespan
respectively.
Results of an in vitro study, using laser diffraction analysis 1171and CIC the inter-device variation with respect to PSD was
negligible, whereas the X50-value for BUD ranged from 2.7
to 3.0 mm which is statistically significant. The data in Fig. 4
are for one particular device producing a representative
aerosol and each data point in Fig. 4 is the mean of five
doses taken from the start (S), middle (M) or end (E) of the
inhaler’s lifespan. We also checked the size distributions in
the aerosols from the FP 50 and 250 mg pMDIs and found
that the FP 50 mg has a much smaller median diameter (X50
is 2.7 mm) than the FP 125 mg. In contrast, the FP 250
appeared to deliver significantly larger particles with
a median diameter of 4.2 mm (data not shown).
Fig. 4 also shows that the PSDs of all four pMDIs remained
rather constantwithin their lifespan.The relativeair humidity
within the range from30 to 75% hadno significant influence on
particle size distribution. For FP and BUD the inter-device
variations were significantly larger than for BDP and CIC.
The influence of the flow rate on the particle size distri-
bution in the aerosol is shown in Fig. 5. This figure demon-
strates the small effects of the flow rate on the PSD for all 4
tested devices within the range between 10 and 30 l/min.
Due to differences in metered dose, mouthpiece retention
and size distribution in the aerosol, different fine particle
mass fractions (FPF< 5 mmas percent of label claim) may be
expected. This is shown in Fig. 6. All three pMDIs of the same
type showed a very high consistency in mean delivered fine
particle mass fraction, the fraction< 5.0 mm being highest
for the CIC pMDI. The aerosols from the FP and BUD pMDI
contained only very few particles<1 mm but for the BDP and
CIC pMDI nearly 15% of the delivered aerosol was in the
particle range of <1 mm. There were also considerable
differences for the fraction 3.1e5 mm, between FP and BUD
on the one hand (respectively 29% and 24% of the label claim)
and BDP and CIC on the other (approx. 10% for both). For the
fraction 1.1e3.1 mmtheCICpMDI scoredbest (55%), followed
by BDP (44%), BUD (42%) and FP (39%).
Discussion
To our knowledge, this is the first study to compare the in
vitro performance of four different ICS pMDIs including FP,
BUD, BDP, and CIC at three different flow rates and taking
lifespan and ambient humidity conditions into account. Most0
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Figure 5 The particle size distribution in the aerosol as
function of the flow rate. FPZ fluticasone 125 mg/dose;
BUDZ budesonide 200 mg/dose; BDPZ beclomethasone
100 mg/dose; CICZ ciclesonide 160 mg/dose.previous studies dealt with single pMDIs.10e15 Terzano
studied the particle characteristics of FP, BDP, and fluniso-
lide in vitro at two different flow rates (30 and 60 l/min).16
Feddah compared the in vitro performance of three ICS DPIs
with pMDIs containing the samedrugs (FP, BUD and BDP) in an
impactor at three different flow rates (30, 60 and 90 l/min)
but their study did not include BDP and CIC.17 Dalby, Barry
and Stein also compared the performance of three different
pMDIs, but their comparisons included other types of drugs,
like salmeterol, salbutamol, and cromolyn sodium.18e20
Fig. 1 shows that noneof the pMDIs testeddelivered amean
dose corresponding with the label claim. The spread found in
delivered dose was relatively high for FP and also significant
for BUD. For the BUD pMDI this was the result of a random
variation, showing a few extremes towards lower values
varying between 52% and 79% of the label claim (Fig. 2b).
However, forFPa gradual and significant decrease in delivered
dosewas obtained over the lifespan of the pMDI. This decrease
appeared to be consistent for 15 devices taken from five
different batches as shown in Fig. 3. On average (for all fifteen
devices) themean of the doses 11e20 from this pMDI was 106%
of the label claim versus only 63% for the mean of the doses
92e100. This reduction is not only statistically significant, but
also of clinical importance. We did not find an explanation for
the inconsistencies found. However, these results point at the
importance of knowing which doses from FP and BUD are used
for in vitro studies as well as for clinical trials.
For all four types of pMDIs the delivered dose is lower
than the metered dose due to some retention in the
mouthpiece. As summarised in Table 1 mouthpieces have
different shapes and dimensions; only those of CIC and BDP
are the same. We found a 15% reduction for the mouthpiece
retention of BDP and CIC by shortening the distance of the
nozzle to the mouthpiece end to 21.5 mm. Shortening also
appeared to influence the PSD in the aerosol. For BDP the
X50-value decreased from 1.95 to 1.79 mm; for CIC the
decrease was from 2.02 to 1.8 mm. Mouthpiece shortening
may also have consequences for the deposition in the
mouth and valved holding chambers however. The net
result of all these effects has to be studied.
Regarding the particle size distributions in the aerosols
(Figs. 4e6) previous findings obtained with cascade
impactor analysis are confirmed.10,17,19,20 BDP and CIC
pMDIs deliver much finer particles than FP and BUD pMDIs.
The data in Fig. 6 suggest that BDP and CIC produce the
highest mass fractions within the size rang of <3.1 mm and
therefore are most appropriate for use in children because
of their smaller airways. The relatively high fraction of
particles <1.1 mm in the aerosols from the BDP and CIC is
likely to be exhaled to a large extent again, unless a rela-
tively long breathhold period is established.21,22
The PSDs for all four pMDIs do change statistically signifi-
cant, butwe do not think this is clinically relevantwithin their
lifespan, nor when the flow rate or relative humidity is varied
between 10 and 30 l/min, respectively 30 and 75%.
In contrast with most previous studies we used a laser
diffraction technique for the characterisation of the
particle size distribution in the aerosol. With the laser
diffraction technique the size distribution of individual
doses can be measured more reproducibly than with
impactors, which suffer from variable losses in the valve,
actuator, and USP throat.20 Therefore, the laser diffraction
flow rate (l/min)
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Figure 6 The size distribution within the fine particle fraction as percent of label claim based upon the mean delivered dose from
the pMDI at 20 l/min. FPZ fluticasone 125 mg/dose; BUDZ budesonide 200 mg/dose; BDPZ beclomethasone 100 mg/dose;
CICZ ciclesonide 160 mg/dose.
1172 T.W. de Vries et al.technique enables a better assessment of the spread in the
fine particle dose in the emitted aerosol. There is
a discrepancy between previously published data from
cascade impactor analysis and the laser diffraction data in
this study for the same pMDIs. For instance, we found
a volume median diameter of 1.9 mm for BDP (Fig. 4). Leach
and Stein referred for BDP to an average particle size of
approximately 1 mm; and from their cascade impactor data
mass median aerodynamic diameters (MMADs) of
0.9e1.0 mm can be calculated.7,20 The reason for the
different results may be losses in the induction port. For
BDP these losses are within the range from 20 to 30% of the
label claim (at approx. 30 l/min). Partly as a result of that,
cumulative fine particle fractions collected in the impactor
were only between 40 and 50% of the label claim.20 With
the laser diffraction technique there are no losses in an
induction port and the mean delivered dose for BDP in our
study was more than 70%. Possibly classification occurs in
the throat of an impactor, as a result of which the size
distribution within the remaining aerosol fraction is
changed. Moreover, the evaporation during longer travel-
ling distance in cascade impactors is likely to result in an
overestimation of the fine particles. There are more basic
differences between cascade impactor and laser diffraction
technique, but it is very unlikely that the differences in
median diameters obtained with both techniques are the
result of that.Conclusions
In this study we show that the in vitro evaluation of ICS
pMDIs under well-controlled conditions is mandatory for
adequate evaluation of drug delivery studies in patients.
We have demonstrated that the performance may vary over
the lifespan of the pMDI and the fine particle fraction
differs relevantly between different ICS. Design, such as
the length of the mouthpiece, significantly influences dose
delivery. We found that the delivered dose of FP 125 and250 decreased significantly during its lifespan, and in some
of the BUD pMDIs the first delivered doses were significantly
lower. Although our data are consistent, they have to be
confirmed by others and the clinical relevance should be
investigated. The particles of CIC and BDP are the most
appropriate for paediatric use. Our results partly confirmed
earlier studies.
Before testing a combination of valved holding chambers
and pMDIs, the performance of the pMDI itself should be
known in relation to the environmental conditions and the
inspiratory flow rate. Furthermore it is important to realise
that there may be a significant inter-dose spread as well as
inter-device variations regarding delivered dose and PSD.
Particularly an inter-device spread makes it necessary that
the same pMDI is used for comparison of data obtained with
and without holding chamber. Knowledge of in vitro
performance is essential to value important in vivo studies.
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